MREO

Business Context and Reporting Period

Company: Mereo Biopharma Group Plc (MREO)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Mereo is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for rare diseases. Its core pipeline includes setrusumab for Osteogenesis Imperfecta (OI) and alvelestat for Alpha-1 Antitrypsin Deficiency (AATD). The company operates as a single segment and relies on strategic partnerships (e.g., Ultragenyx, AstraZeneca) and licensing agreements to fund development and commercialization.

Key Financial Metrics

Note: The company has never generated revenue from product sales. 2023 revenue consisted of milestone payments from Ultragenyx and ReproNovo.

Material Changes vs. Prior Period

• Revenue Decline: Revenue dropped to zero in 2024 compared to $10.0 million in 2023. The 2023 figure included a $9.0 million milestone from Ultragenyx and a $1.0 million upfront payment from ReproNovo, neither of which occurred in 2024.
• Increased Operating Loss: Net loss widened by $13.8 million (47% increase) to $43.3 million, driven by higher operating expenses.
• R&D Expense Growth: R&D expenses increased by $3.5 million to $20.9 million. This was primarily due to increased spending on alvelestat ($6.2M increase) for Phase 3 preparation and setrusumab ($2.6M increase) for European commercialization activities. Conversely, etigilimab expenses decreased by $5.5 million as the Phase 1b/2 study wound down.
• G&A Expense Growth: G&A expenses rose by $8.0 million to $26.4 million, largely due to pre-commercial activities for setrusumab in Europe and costs associated with transitioning to a U.S. domestic reporting regime.
• Liquidity Improvement: Cash balances increased by $12.4 million to $69.8 million, primarily fueled by a $46.2 million net proceeds from an underwritten registered direct offering in June 2024.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management expects current cash resources to fund operations and capital expenditures into 2027. However, the company anticipates needing additional external funding to complete development plans and commercialize products.
• Clinical Progress:
  • Setrusumab: Phase 3 enrollment (Orbit and Cosmic studies) completed in April 2024. The company retains commercial rights in Europe and the U.K.
  • Alvelestat: Preparing for a global Phase 3 study in AATD-LD. Regulatory guidance has been received from the FDA and EMA.
• Key Risks:
  • Capital Requirements: Significant additional funding is required; failure to raise capital could force delays or elimination of R&D programs.
  • Regulatory Uncertainty: No product candidates have received regulatory approval. Success depends on clinical trial outcomes and regulatory decisions.
  • Partnership Dependence: Reliance on partners (Ultragenyx, AstraZeneca) for development and commercialization of key assets.
  • Competition: Intense competition in rare disease and oncology sectors from large pharmaceutical companies.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $69.8 million cash balance against the projected burn rate to confirm the "into 2027" liquidity estimate.
• Phase 3 Readiness: Confirm the timeline and budget for the initiation of the alvelestat Phase 3 trial, which is a major upcoming cost driver.
• Partnership Milestones: Monitor the status of the Ultragenyx partnership for setrusumab and the AstraZeneca agreement for alvelestat for potential future milestone payments or equity issuances.
• Regulatory Filings: Track upcoming data readouts from the setrusumab Phase 3 studies and any regulatory feedback on the alvelestat Phase 3 design.
• Debt Conversion: Note the subsequent event (February 2025) where the Novartis Loan Note was converted into equity, eliminating a significant debt obligation but increasing share count.